New Leaf Venture Partners

Truveris is a health information technology company based in New York that focuses on bringing transparency to the prescription drug ecosystem. Founded in 2009, Truveris develops management tools for sponsors and payers of claims under prescription benefit plans. Its platform offers data-driven insights to help customers, including patients, employers, retailers, pharmacy benefits stakeholders, and manufacturers, manage rising costs and market access challenges effectively. The company's solutions include RxChoice, TruBid, and RxDash, which serve various entities in the pharmacy value chain.

Qlaris Bio is a clinical-stage biotechnology company based in Wellesley, Massachusetts, founded in 2017. The company specializes in developing innovative therapies for serious and debilitating ophthalmic diseases, with a focus on addressing episcleral venous pressure (EVP), a significant component of intraocular pressure (IOP). Qlaris Bio's lead therapy, QLS-101, aims to reduce IOP, thereby mitigating the risk of blindness in conditions such as Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets other high unmet need conditions related to disturbances in intraocular pressure, including a progressive pediatric rare disease with limited effective therapies.

Flosonics Medical is a Canadian medical device company founded in 2017, specializing in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. Its flagship product, the FloPatch, is a wearable ultrasound sensor designed to monitor blood flow in patients post-clinical intervention, thereby addressing critical clinical needs. The FloPatch is particularly beneficial for healthcare professionals, including physicians, nurses, and paramedics, operating in various high-pressure environments such as ambulances, emergency departments, operating rooms, and intensive care units. The device is notable for its portability, wireless connectivity with tablets and other medical equipment, and user-friendly functionality, all of which contribute to improved patient care in urgent medical situations. Flosonics Medical, previously known as Ke2 Technologies, rebranded in September 2017.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Arvist enhances warehouse operations by employing AI-powered digital twin technology. It uses existing data and security camera footage, along with unique marker technology, to optimize costs, improve efficiency, and bolster safety without additional infrastructure expenses.

Star Therapeutics aims to develop therapies for numerous rare diseases by identifying those with shared biological pathways. This approach enables the creation of single treatments capable of addressing multiple conditions, thereby expanding pharmaceutical pipelines.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Arine Inc. is a San Francisco-based company that specializes in developing a clinical learning and analytic response engine aimed at enhancing medication management and patient care. Founded in 2017, Arine utilizes a data-driven approach to optimize medications and improve health outcomes for patients and their families. The company's platform aggregates and analyzes clinical, social, and behavioral data to identify gaps in patient care, allowing for tailored and actionable medication recommendations. By partnering expert clinicians with data scientists and engineers, Arine focuses on delivering timely interventions that guide patients throughout their healthcare journey, ultimately aiming to lower costs and improve the quality of care.

Star Therapeutics aims to develop therapies for numerous rare diseases by identifying those with shared biological pathways. This approach enables the creation of single treatments capable of addressing multiple conditions, thereby expanding pharmaceutical pipelines.

Electra Therapeutics is a clinical stage biotechnology company focused on developing therapies aimed at treating immunological diseases and cancer. The company specializes in targeting signal regulatory proteins (SIRP) to deplete pathological immune cells. Its lead product candidate, ELA026, is a monoclonal antibody currently in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition with no existing approved treatments. In addition to ELA026, Electra has two preclinical programs under development, highlighting its commitment to addressing unmet medical needs in the field of immunology and oncology.

Asimily, Inc. is a technology company that specializes in developing a risk remediation platform tailored for the healthcare sector. Established in 2017 and based in Sunnyvale, California, Asimily focuses on securing critical medical devices that are essential for delivering safe and reliable patient care. The company offers a comprehensive management platform that employs distributed analytics to monitor and assess the security posture of both connected and standalone medical devices across healthcare organizations. By leveraging a robust knowledge base of medical devices and protocols, Asimily identifies and prioritizes vulnerabilities, providing actionable intelligence for remediation. Their platform utilizes big data and machine learning to deliver continuous insights and alerts, enabling healthcare providers to detect anomalous behavior and enhance the security of their IT assets while ensuring the safety of patients and resources.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Cleerly is a healthcare company developing digital care pathways to prevent heart attacks by establishing a new standard of care for coronary artery disease. The company combines clinical science with next-generation AI to deliver actionable insights across the heart care pathway, including a non-invasive platform that quantifies and characterizes plaque buildup in heart arteries. Its solutions aim to help healthcare providers identify at-risk patients early and support cost-effective prevention, ultimately improving cardiovascular outcomes and delivering value to the health system.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.

BrightInsight operates a digital health platform tailored for biopharma and medtech companies. Founded in 2017 and headquartered in San Jose, California, the company provides an Internet of Things (IoT) solution designed to support the development, scaling, and maintenance of regulated digital health products and services. The BrightInsight platform captures, transmits, and analyzes data from various sources, including medical devices, combination products, applications, and digital therapeutics, all while adhering to security, privacy, and regulatory standards. This integrated approach enables clients to enhance patient adherence and engagement, accelerate market entry, and reduce implementation costs across diverse products and global markets.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

TigerConnect is a leading provider of secure, real-time communication solutions in healthcare. Its platform facilitates teamwork among doctors, nurses, patients, and care providers through text, video, and voice communication. Trusted by over 4,000 organizations, TigerConnect maintains high uptime and processes millions of messages daily. Headquartered in Santa Monica, California, the company was founded in 2010.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

Saniona is a pharmaceutical company focused on discovering and developing medicines that modulate ion channels to treat central nervous system disorders, autoimmune diseases, metabolic diseases, and pain. It operates a technology platform that enables investigation of ion channel targets, including GABAA receptors, nicotinic acetylcholine receptors, and potassium channels, to create selective modulators. Its product pipeline includes Tesomet, SAN711, SAN903, and SAN2219; Tesomet has advanced to mid-stage trials for rare eating disorders, SAN711 completed a Phase 1 trial for neuropathic pain, SAN903 is positioned to enter Phase 1 trials for inflammatory and fibrotic disorders, and SAN2219 is in development. Saniona operates in the United States, Sweden, Germany, Denmark, and the United Kingdom.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

BrightInsight operates a digital health platform tailored for biopharma and medtech companies. Founded in 2017 and headquartered in San Jose, California, the company provides an Internet of Things (IoT) solution designed to support the development, scaling, and maintenance of regulated digital health products and services. The BrightInsight platform captures, transmits, and analyzes data from various sources, including medical devices, combination products, applications, and digital therapeutics, all while adhering to security, privacy, and regulatory standards. This integrated approach enables clients to enhance patient adherence and engagement, accelerate market entry, and reduce implementation costs across diverse products and global markets.

Rallybio is a clinical-stage biopharmaceutical company focused on developing therapies for severe and rare diseases. Its programs cover hematology, immuno-inflammation, maternal-fetal health and metabolic disorders, with a lead candidate aimed at preventing fetal and neonatal alloimmune thrombocytopenia, a life-threatening condition that can cause bleeding in fetuses and newborns. Founded in 2018 and based in New Haven, Connecticut, Rallybio develops therapies across antibodies, small molecules and engineered proteins to address unmet needs in rare diseases. Guided by experienced biopharma leadership, the company emphasizes translating biology into transformative therapies for underserved patients.

AiCure, LLC is a New York-based company that specializes in developing scalable medication adherence solutions and intelligent medical assistant technologies. Utilizing a visual recognition platform, AiCure's software monitors patient progress through mobile devices, confirming medication ingestion in clinical trials and among high-risk populations. The platform employs patented facial recognition and motion-sensing technology to identify patients and medications, detect diversion, and capture evidence of adherence in real-time. This data enables immediate intervention and longitudinal tracking of adherence patterns, ultimately enhancing treatment outcomes and reducing healthcare costs. AiCure's capabilities also facilitate remote patient engagement in clinical trials by measuring digital biomarkers and monitoring patient dosing. Founded in 2010, AiCure aims to transform healthcare delivery systems through advanced data analytics and artificial intelligence.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

BrightInsight operates a digital health platform tailored for biopharma and medtech companies. Founded in 2017 and headquartered in San Jose, California, the company provides an Internet of Things (IoT) solution designed to support the development, scaling, and maintenance of regulated digital health products and services. The BrightInsight platform captures, transmits, and analyzes data from various sources, including medical devices, combination products, applications, and digital therapeutics, all while adhering to security, privacy, and regulatory standards. This integrated approach enables clients to enhance patient adherence and engagement, accelerate market entry, and reduce implementation costs across diverse products and global markets.

Passage Bio is a gene therapy company dedicated to developing transformative treatments for rare, monogenic central nervous system disorders. It has an integrated pipeline of five AAV-delivered therapeutics and collaborates with the University of Pennsylvania's Gene Therapy Program for preclinical work.

Qlaris Bio is a clinical-stage biotechnology company based in Wellesley, Massachusetts, founded in 2017. The company specializes in developing innovative therapies for serious and debilitating ophthalmic diseases, with a focus on addressing episcleral venous pressure (EVP), a significant component of intraocular pressure (IOP). Qlaris Bio's lead therapy, QLS-101, aims to reduce IOP, thereby mitigating the risk of blindness in conditions such as Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets other high unmet need conditions related to disturbances in intraocular pressure, including a progressive pediatric rare disease with limited effective therapies.

Renovacor, Inc., established in 2013 and headquartered in Philadelphia, Pennsylvania, is a biopharmaceutical company dedicated to developing transformative gene therapies for cardiovascular diseases. Currently in the preclinical stage, Renovacor's primary focus is on creating a recombinant adeno-associated virus (AAV)-based gene therapy targeting patients with dilated cardiomyopathy (DCM) caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This condition affects approximately 35,000 individuals in the United States and Europe, qualifying it as an orphan disease. Renovacor aims to improve patient outcomes by potentially preventing disease progression through a BAG3 gene replacement therapy, given the current five-year survival rate of only 50% for DCM patients despite standard care.

Passage Bio is a gene therapy company dedicated to developing transformative treatments for rare, monogenic central nervous system disorders. It has an integrated pipeline of five AAV-delivered therapeutics and collaborates with the University of Pennsylvania's Gene Therapy Program for preclinical work.

Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

IRLAB Therapeutics AB is a Swedish research and development company focused on creating innovative drug treatments for neurological disorders, particularly Parkinson's disease. The company has developed several clinical candidates, including Mesdopetam, a dopamine D3 receptor antagonist that has completed Phase IIa trials for dyskinesia, and IRL752, which has also progressed through Phase IIa trials for postural dysfunction. In addition to these, IRLAB is advancing other research initiatives aimed at addressing neurodegenerative conditions and the effects of aging. These include programs designed to develop alternatives to levodopa, a common Parkinson's treatment, and additional compounds targeting various dysfunctions associated with Parkinson's disease. Based in Gothenburg, Sweden, IRLAB is committed to enhancing the quality of life for patients suffering from neurological and psychiatric illnesses through its innovative therapeutic approaches.

Neurana Pharmaceuticals is a biotechnology company based in San Diego, California, focused on developing treatments for neuromuscular conditions. Founded in 2013, the company specializes in addressing acute and painful muscle spasms of the neck and back. Neurana's flagship therapeutic compound is Tolperisone, which treats musculoskeletal conditions such as neuromuscular spasms and spasticity without causing sedation. The company aims to provide fast relief for patients suffering from these conditions.

Rallybio is a clinical-stage biopharmaceutical company focused on developing therapies for severe and rare diseases. Its programs cover hematology, immuno-inflammation, maternal-fetal health and metabolic disorders, with a lead candidate aimed at preventing fetal and neonatal alloimmune thrombocytopenia, a life-threatening condition that can cause bleeding in fetuses and newborns. Founded in 2018 and based in New Haven, Connecticut, Rallybio develops therapies across antibodies, small molecules and engineered proteins to address unmet needs in rare diseases. Guided by experienced biopharma leadership, the company emphasizes translating biology into transformative therapies for underserved patients.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Technology Will Save Us Ltd. is a London-based company that specializes in developing DIY gadget kits and hardware aimed at families, educators, and young people. Founded in 2011, the company offers a diverse range of innovative products, including handheld games consoles, electronic synthesizers, conductive dough, DIY speaker kits, moisture sensors, and an open-source electronics platform. Its mission is to inspire creativity and innovation among young people by providing hands-on technology experiences. The company serves various educational environments, including classrooms, after-school clubs, and home schools, and has successfully reached children in over 87 countries. With a dedicated team of designers, educators, and engineers, Technology Will Save Us engages closely with children during the design process, ensuring that its products align with their interests and learning needs. The company's offerings are available through kiosks in the UK and online, making them accessible to a global audience.

Braeburn Inc. is a pharmaceutical company focused on developing and commercializing treatments for serious central nervous system disorders, with a primary emphasis on opioid addiction. Founded in 2012 and headquartered in Plymouth Meeting, Pennsylvania, Braeburn aims to provide innovative solutions for individuals affected by opioid use disorder (OUD). The company's lead product candidate, BRIXADI, is an extended-release injectable formulation of buprenorphine designed for the treatment of moderate to severe OUD. Braeburn is committed to advancing next-generation therapies that offer individualized dosing regimens and delivery options, striving to improve care for patients and address the growing challenges associated with addiction.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

AiCure, LLC is a New York-based company that specializes in developing scalable medication adherence solutions and intelligent medical assistant technologies. Utilizing a visual recognition platform, AiCure's software monitors patient progress through mobile devices, confirming medication ingestion in clinical trials and among high-risk populations. The platform employs patented facial recognition and motion-sensing technology to identify patients and medications, detect diversion, and capture evidence of adherence in real-time. This data enables immediate intervention and longitudinal tracking of adherence patterns, ultimately enhancing treatment outcomes and reducing healthcare costs. AiCure's capabilities also facilitate remote patient engagement in clinical trials by measuring digital biomarkers and monitoring patient dosing. Founded in 2010, AiCure aims to transform healthcare delivery systems through advanced data analytics and artificial intelligence.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

Truveris is a health information technology company based in New York that focuses on bringing transparency to the prescription drug ecosystem. Founded in 2009, Truveris develops management tools for sponsors and payers of claims under prescription benefit plans. Its platform offers data-driven insights to help customers, including patients, employers, retailers, pharmacy benefits stakeholders, and manufacturers, manage rising costs and market access challenges effectively. The company's solutions include RxChoice, TruBid, and RxDash, which serve various entities in the pharmacy value chain.

Neuronetics is a medical technology company that designs, develops, and markets non-invasive therapies for psychiatric disorders. Its flagship product, NeuroStar Advanced Therapy System, uses transcranial magnetic stimulation to treat adult patients with major depressive disorder in office-based settings.

Deciphera Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for cancer patients. It focuses on kinase biology, leveraging its proprietary switch-control kinase inhibitor platform to create a diverse pipeline of drug candidates. Its lead product, QINLOCK®, is approved in several countries for treating fourth-line gastrointestinal stromal tumors (GIST). The company also has multiple clinical-stage and research-stage programs targeting various cancers.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing novel anti-infectives to combat multi-drug resistant pathogens. Its lead product, sulopenem, is a penem antibiotic with both oral and intravenous formulations, currently in Phase III trials for treating various urinary tract infections and intra-abdominal infections.

CRISPR Therapeutics specializes in developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. This technology enables precise, directed changes to genomic DNA for treating serious human diseases. The company focuses on various disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

Bluesight operates as a healthcare technology company specializing in supply chain optimization for pharmaceuticals. It offers Medication Intelligence solutions that provide real-time analytics across the entire medication lifecycle, enhancing efficiency, reducing risks, and improving patient safety within hospitals. The core product is an inventory management platform that automates pharmacy kit processing and medication tracking, replacing manual processes to increase operational efficiency and medication visibility.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing novel anti-infectives to combat multi-drug resistant pathogens. Its lead product, sulopenem, is a penem antibiotic with both oral and intravenous formulations, currently in Phase III trials for treating various urinary tract infections and intra-abdominal infections.

AiCure, LLC is a New York-based company that specializes in developing scalable medication adherence solutions and intelligent medical assistant technologies. Utilizing a visual recognition platform, AiCure's software monitors patient progress through mobile devices, confirming medication ingestion in clinical trials and among high-risk populations. The platform employs patented facial recognition and motion-sensing technology to identify patients and medications, detect diversion, and capture evidence of adherence in real-time. This data enables immediate intervention and longitudinal tracking of adherence patterns, ultimately enhancing treatment outcomes and reducing healthcare costs. AiCure's capabilities also facilitate remote patient engagement in clinical trials by measuring digital biomarkers and monitoring patient dosing. Founded in 2010, AiCure aims to transform healthcare delivery systems through advanced data analytics and artificial intelligence.

True North Therapeutics is a biotechnology company based in South San Francisco, California, founded in 2013 as a spin-out of iPierian. The company focuses on developing therapies that target the classical pathway of the immune system's complement system to address rare diseases with high unmet clinical needs. Its lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway, aiming to treat conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, antibody-mediated rejection, bullous pemphigoid, and other rare diseases in hematologic, kidney transplant, dermatology, and neurological spaces. True North Therapeutics was acquired by Bioverativ Inc.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Deciphera Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for cancer patients. It focuses on kinase biology, leveraging its proprietary switch-control kinase inhibitor platform to create a diverse pipeline of drug candidates. Its lead product, QINLOCK®, is approved in several countries for treating fourth-line gastrointestinal stromal tumors (GIST). The company also has multiple clinical-stage and research-stage programs targeting various cancers.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

ReShape Lifesciences is a medical device company focused on technologies to treat obesity and metabolic diseases. The company develops and commercializes products designed to provide less invasive options for weight loss, including the Lap-Band System, an adjustable gastric banding device for long-term obesity management. It also has the ReShape Vest system, an investigational laparoscopically implanted device that wraps around the stomach and is designed to support weight loss without permanent changes to the GI tract; the Vest is primarily marketed outside the United States. The company traces its origins to EnteroMedics and adopted the ReShape Lifesciences name in 2017. It is headquartered in San Clemente, California, and operates in multiple international markets.

Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, designing, optimizing, and producing stereopure oligonucleotides through its PRISM platform. The company aims to address genetically defined diseases by reducing harmful protein expression or correcting dysfunctional proteins, employing modalities such as RNA editing, antisense silencing, and RNA interference. Its programs span neurological and neuromuscular conditions, reflecting an emphasis on central nervous system targets. Wave collaborates with Pfizer and Takeda on research, development, and commercialization of stereopure oligonucleotide therapeutics and antisense therapies. Founded in 2012 and based in Singapore, the company seeks to unlock the broader potential of RNA medicines to improve patient outcomes.

Principia Biopharma Inc. is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead product, rilzabrutinib, is an inhibitor undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 trials for immune thrombocytopenia and Phase 2 trials for IgG4-related disease. Additionally, Principia is developing PRN2246/SAR442168, which is in Phase II for multiple sclerosis and other central nervous system conditions, alongside PRN473, a drug candidate in Phase I trials for immune-mediated diseases. Principia Biopharma maintains a collaboration agreement with Genzyme Corporation for the development of treatments for MS and other CNS diseases. Originally incorporated in 2008, the company is dedicated to addressing significant unmet medical needs in immunology and oncology through its innovative drug development platform.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on developing innovative medicines for chronic pain management and neurogenic disorders. The company specializes in targeting P2X3 receptors found in nerve fibers, creating small molecule compounds designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy. Afferent's lead compound, AF-219, has successfully completed two Phase 1 clinical studies, positioning the company to advance its portfolio of therapeutics aimed at improving the quality of life for patients suffering from various pain-related ailments. Founded in 2009, Afferent Pharmaceuticals is dedicated to advancing the understanding and treatment of chronic pain through scientific innovation.

Advanced Cell Diagnostics, Inc. is a biotechnology company specializing in the development and commercialization of cell and tissue-based diagnostic tests for personalized medicine. Founded in 2007 and based in Hayward, California, the company utilizes its proprietary RNAscope technology, a multiplex fluorescent and chromogenic in situ hybridization platform, to detect and quantify RNA biomarkers at single molecule sensitivity. Its product offerings include RNAscope manual assays and reagent kits, automated tissue staining solutions, catalog probes, and software for quantitative analysis of RNA in situ hybridization samples. Advanced Cell Diagnostics also provides pharmaceutical assay services to aid in understanding disease mechanisms and support preclinical and clinical research, including companion diagnostic assay development. The company serves a global market through a network of distributors in various countries and has a direct online presence.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Neuronetics is a medical technology company that designs, develops, and markets non-invasive therapies for psychiatric disorders. Its flagship product, NeuroStar Advanced Therapy System, uses transcranial magnetic stimulation to treat adult patients with major depressive disorder in office-based settings.

Dimension Therapeutics, Inc. is a gene therapy company based in Cambridge, Massachusetts, specializing in the development of innovative treatments for rare and metabolic diseases associated with the liver. Founded in 2013, the company has a robust pipeline of gene therapy programs, including DTX101 and DTX201 for hemophilia B and A, respectively. Additionally, its portfolio encompasses DTX301 for ornithine transcarbamylase deficiency, DTX401 for glycogen storage disease type Ia, DTX501 for phenylketonuria, DTX701 for Wilson disease, and DTX601 for citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, gaining access to a significant portfolio of patents related to adeno-associated virus (AAV) therapeutics. This collaboration supports the company's aim to advance its gene therapy platform and enhance its product development capabilities in the treatment of rare diseases. Dimension Therapeutics operates as a subsidiary of Ultragenyx Pharmaceutical Inc. since November 2017.

Edge Therapeutics is a clinical-stage biotechnology company based in Berkeley Heights, New Jersey, focused on developing innovative therapies for acute, life-threatening neurological conditions. Established in 2009, the company aims to transform treatment paradigms in hospital settings through its proprietary platform, Precisa, which facilitates the creation of polymer-based therapeutics designed for targeted delivery to injury sites. The lead product candidate, EG-1962, is currently undergoing evaluation in the Phase 3 NEWTON 2 study, aimed at improving outcomes for patients suffering from aneurysmal subarachnoid hemorrhage (aSAH). Additionally, Edge is assessing EG-1964 as a potential prophylactic treatment for chronic subdural hematoma, aimed at preventing recurrent bleeding on the brain's surface. Through these efforts, Edge Therapeutics seeks to address serious unmet medical needs in the field of neurology.

Bluesight operates as a healthcare technology company specializing in supply chain optimization for pharmaceuticals. It offers Medication Intelligence solutions that provide real-time analytics across the entire medication lifecycle, enhancing efficiency, reducing risks, and improving patient safety within hospitals. The core product is an inventory management platform that automates pharmacy kit processing and medication tracking, replacing manual processes to increase operational efficiency and medication visibility.

CardioKinetix develops transcatheter implants for treating heart failure. Its flagship product is Parachute, a ventricular partitioning device designed to improve overall cardiac function in patients who have experienced a heart attack. The company serves customers primarily in the United States and Europe.

QPID Health, Inc. is a healthcare IT software company based in Boston, Massachusetts, with additional locations in San Diego, California. The company focuses on delivering a health record intelligence platform that enhances the utility of electronic health records (EHRs) for healthcare institutions and clinicians. Its primary product, the Queriable Programmable Inference Dossier (QPID), enables real-time, clinician-directed queries and analytics at the point of care. By aggregating and processing EHR data, QPID offers context-sensitive information that integrates seamlessly into clinical workflows, thereby improving clinician productivity and decision-making. The platform employs natural language processing and machine learning techniques to provide tailored clinical insights, helping healthcare organizations optimize operations, reduce costs, and enhance patient outcomes. Founded in 2013 by Dr. Michael Zalis and Dr. Mitch Harris, QPID Health addresses the growing need for effective data utilization in healthcare settings.

Principia Biopharma Inc. is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead product, rilzabrutinib, is an inhibitor undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 trials for immune thrombocytopenia and Phase 2 trials for IgG4-related disease. Additionally, Principia is developing PRN2246/SAR442168, which is in Phase II for multiple sclerosis and other central nervous system conditions, alongside PRN473, a drug candidate in Phase I trials for immune-mediated diseases. Principia Biopharma maintains a collaboration agreement with Genzyme Corporation for the development of treatments for MS and other CNS diseases. Originally incorporated in 2008, the company is dedicated to addressing significant unmet medical needs in immunology and oncology through its innovative drug development platform.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

TigerConnect is a leading provider of secure, real-time communication solutions in healthcare. Its platform facilitates teamwork among doctors, nurses, patients, and care providers through text, video, and voice communication. Trusted by over 4,000 organizations, TigerConnect maintains high uptime and processes millions of messages daily. Headquartered in Santa Monica, California, the company was founded in 2010.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

Catalyst Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for rare, debilitating neuromuscular and neurological diseases. Its primary product, Firdapse, treats Lambert-Eaton Myasthenic Syndrome and has potential applications in other neuromuscular disorders.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company based in Newton, Massachusetts, focused on the discovery and development of innovative drug therapies for cancer and other significant diseases. The company specializes in small molecule selective inhibitors of nuclear export (SINE) compounds, targeting the nuclear export protein exportin 1. Its lead product, XPOVIO, is approved in the U.S. for treating multiple myeloma in various settings. Karyopharm is advancing several clinical trials, including BOSTON and STORM for multiple myeloma, SADAL for diffuse large B-cell lymphoma, and SEAL for liposarcoma. Additionally, it is exploring the treatment of endometrial cancer through the SIENDO trial and glioblastoma multiforme in the KING trial. The company maintains collaborations to facilitate clinical trials and research efforts, including projects related to COVID-19. Karyopharm continues to develop various investigational programs aimed at expanding its therapeutic portfolio.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

Bluesight operates as a healthcare technology company specializing in supply chain optimization for pharmaceuticals. It offers Medication Intelligence solutions that provide real-time analytics across the entire medication lifecycle, enhancing efficiency, reducing risks, and improving patient safety within hospitals. The core product is an inventory management platform that automates pharmacy kit processing and medication tracking, replacing manual processes to increase operational efficiency and medication visibility.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Founded in 2008, Treato Ltd. operates Treato, a platform that aggregates and analyzes patient experiences from online health discussions. It provides insights for patients, healthcare professionals, pharmaceutical companies, and other organizations to understand patient needs and attitudes.

iRhythm Technologies is a digital healthcare company specializing in ambulatory cardiac monitoring solutions. It offers the Zio Patch, a wire-free, wearable biosensor that records ECG data for up to 14 days, aiding physicians in diagnosing arrhythmias efficiently.

Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.

CardioKinetix develops transcatheter implants for treating heart failure. Its flagship product is Parachute, a ventricular partitioning device designed to improve overall cardiac function in patients who have experienced a heart attack. The company serves customers primarily in the United States and Europe.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing innovative tools for clinicians to enhance the care of critically ill patients, particularly through continuous glucose monitoring. The company's primary product, GluCath, is an intravascular device designed to provide real-time blood glucose measurements for hospitalized patients, facilitating better management of their glucose levels. By focusing on continuous monitoring, GluMetrics aims to improve patient outcomes in critical care settings.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.

MEI Pharma is a biopharmaceutical company focused on developing novel therapies for cancer. Its pipeline includes Zandelisib (PI3K inhibitor) and Voruciclib (CDK9 inhibitor), both in clinical trials, as well as Pracinostat (HDAC inhibitor). The company collaborates with other pharmaceutical companies for drug development.

Advanced Cell Diagnostics, Inc. is a biotechnology company specializing in the development and commercialization of cell and tissue-based diagnostic tests for personalized medicine. Founded in 2007 and based in Hayward, California, the company utilizes its proprietary RNAscope technology, a multiplex fluorescent and chromogenic in situ hybridization platform, to detect and quantify RNA biomarkers at single molecule sensitivity. Its product offerings include RNAscope manual assays and reagent kits, automated tissue staining solutions, catalog probes, and software for quantitative analysis of RNA in situ hybridization samples. Advanced Cell Diagnostics also provides pharmaceutical assay services to aid in understanding disease mechanisms and support preclinical and clinical research, including companion diagnostic assay development. The company serves a global market through a network of distributors in various countries and has a direct online presence.

Principia Biopharma Inc. is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead product, rilzabrutinib, is an inhibitor undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 trials for immune thrombocytopenia and Phase 2 trials for IgG4-related disease. Additionally, Principia is developing PRN2246/SAR442168, which is in Phase II for multiple sclerosis and other central nervous system conditions, alongside PRN473, a drug candidate in Phase I trials for immune-mediated diseases. Principia Biopharma maintains a collaboration agreement with Genzyme Corporation for the development of treatments for MS and other CNS diseases. Originally incorporated in 2008, the company is dedicated to addressing significant unmet medical needs in immunology and oncology through its innovative drug development platform.

ReShape Lifesciences is a medical device company focused on technologies to treat obesity and metabolic diseases. The company develops and commercializes products designed to provide less invasive options for weight loss, including the Lap-Band System, an adjustable gastric banding device for long-term obesity management. It also has the ReShape Vest system, an investigational laparoscopically implanted device that wraps around the stomach and is designed to support weight loss without permanent changes to the GI tract; the Vest is primarily marketed outside the United States. The company traces its origins to EnteroMedics and adopted the ReShape Lifesciences name in 2017. It is headquartered in San Clemente, California, and operates in multiple international markets.

Access Closure, Inc. is a medical device company based in Mountain View, California, founded in 2002. The company specializes in developing access site management products focused on vascular closure during interventional and diagnostic procedures. Its primary offering is the Mynx delivery system, a vascular closure device designed to seal arteriotomies using a unique water-soluble and extravascular sealant. This sealant expands within the tissue tract by absorbing blood and subcutaneous fluids, effectively addressing the complexities associated with vascular closure. Access Closure aims to enhance patient outcomes and procedural efficiency in the field of vascular access.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company based in San Francisco, California, focused on the discovery and development of small-molecule antiviral therapeutics for viral infections, particularly hepatitis C virus (HCV) and HIV. Founded in 2006, the company is dedicated to creating innovative therapies, including pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride, which target specific proteins of the HCV. Presidio's antiviral therapeutics are designed for daily oral dosing and can be used in combination with other antiviral treatments to enhance efficacy and combat viral resistance. Through its efforts, Presidio aims to provide effective drug therapies to patients dealing with various strains of hepatitis.

IlluminOss Medical, Inc., established in 2007 and headquartered in East Providence, Rhode Island, is a medical device company specializing in orthopedic fracture repair. It designs, develops, and markets products based on its proprietary IlluminOss System, which employs a light-curable polymer within an expandable balloon catheter to create patient-specific intramedullary implants for bone stabilization. This minimally invasive technology is particularly suited for treating osteoporotic and compromised bone. The company's products are CE-marked and FDA-cleared for various anatomical sites and are distributed in several European countries.